Please assess the completion status of the following clinical trial:

Trial Title: Project to Improve Symptoms and Mood in People With Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spinal cord injury (ASIA A-D)~* At least one month post injury~* Meets DSM IV criteria for major depression or dysthymia on the SCID~* At least moderately severe depression (PHQ-9 score \>= 10)~* Within reasonable travel distance to one of the study sites~Exclusion Criteria:~* Current DSM IV alcohol or drug dependence~* History of bipolar disorder or psychosis~* History of \>= 2 suicide attempts or suicide attempt with 5 years~* Current suicidal intent or plan~* Medical contraindications~* Non-English speaker~* Clinically significant cognitive/language impairment~* History of allergic reaction to venlafaxine XR or use of MAO-I with 2 weeks~* Current use of antidepressant medications (will not exclude if on low dose of a tricyclic antidepressant or trazodone for pain, sleep, or bladder), psychotherapy for depression, or electroconvulsive therapy~* Pregnant or lactating women or women of childbearing potential who are not willing to use a reliable form of contraception~* Unstable medical condition, as determined by physical examination, CBC w/ platelets (including hematocrit, hemoglobin, WBC, differential), serum chemistry panel (serum sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose), liver transaminases (AST, ALT), thyroid stimulating hormone (TSH), urinalysis, supine diastolic blood pressure (SDBP) \> 90 mm Hg, or near terminal illness (primary care physician estimates that patient has \< 1 year to live)~* Anticipated major surgical procedures within the 12 weeks of randomization~* Use of an investigational drug within 30 days~* Use of psychoactive medications, including corticosteroids and anticonvulsants, that have not been at a stable dose for at least 2 weeks~* Use of anxiolytic, sedative-hypnotic, or other psychotropic drug or substance (including St. John's Wort) within 7 days of start of double-blind treatment. If the patient is taking a sedative deemed necessary for sleep induction or spasticity, the dosage must have been stable for at least 2 weeks. Use of anticholinergic, low-dose tricyclic antidepressant, GABAergic or adrenergic medications for spasticity are permitted if at a stable dose for at least 2 weeks.~* Refusal to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): identically encapsulated placebo pills 37.5 - 300 mg/day for 12 weeks
- venlafaxine XR (Type: EXPERIMENTAL): venlafaxine XR 37.5 - 300 mg/day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).